AU2001274536A1 - Insulin-like growth factor-binding protein - Google Patents
Insulin-like growth factor-binding proteinInfo
- Publication number
- AU2001274536A1 AU2001274536A1 AU2001274536A AU7453601A AU2001274536A1 AU 2001274536 A1 AU2001274536 A1 AU 2001274536A1 AU 2001274536 A AU2001274536 A AU 2001274536A AU 7453601 A AU7453601 A AU 7453601A AU 2001274536 A1 AU2001274536 A1 AU 2001274536A1
- Authority
- AU
- Australia
- Prior art keywords
- insulin
- growth factor
- binding protein
- protein
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4743—Insulin-like growth factor binding protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-180214 | 2000-06-15 | ||
JP2000180214 | 2000-06-15 | ||
PCT/JP2001/005112 WO2001098493A1 (en) | 2000-06-15 | 2001-06-15 | Insulin-like growth factor-binding protein |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001274536A1 true AU2001274536A1 (en) | 2002-01-02 |
Family
ID=18681357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001274536A Abandoned AU2001274536A1 (en) | 2000-06-15 | 2001-06-15 | Insulin-like growth factor-binding protein |
Country Status (4)
Country | Link |
---|---|
US (3) | US7071160B2 (en) |
EP (1) | EP1295939A4 (en) |
AU (1) | AU2001274536A1 (en) |
WO (1) | WO2001098493A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002950188A0 (en) * | 2002-07-12 | 2002-09-12 | The University Of Adelaide | Altered insulin-like growth factor binding proteins |
US7638605B2 (en) * | 2003-05-01 | 2009-12-29 | ImClone, LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
AU2004278311A1 (en) | 2003-10-03 | 2005-04-14 | Genentech, Inc. | IGF binding proteins |
WO2006041488A1 (en) * | 2003-10-10 | 2006-04-20 | Multicell Technologies, Inc. | Immortalized hepatocytes |
CA2678008C (en) | 2005-06-17 | 2013-07-30 | Imclone Systems Incorporated | Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies |
EA017265B1 (en) * | 2006-02-03 | 2012-11-30 | Имклоун Элэлси | Use of imc-a12 antibody being igf-ir inhibitor for treatment of prostate cancer |
CN106908603B (en) | 2007-01-25 | 2019-04-02 | 霍夫曼-拉罗奇有限公司 | Purposes of the IGFBP-7 in assessment of heart failure |
EP2340262B1 (en) * | 2008-10-14 | 2017-04-05 | National Research Council Canada | Formulations targeting igfbp7 for diagnosis and therapy of cancer |
EP2352514A4 (en) * | 2008-10-29 | 2012-07-25 | Univ Rockefeller | Methods and kits for treating disease by administering insulin-like growth factor binding protein-2 |
US20100316639A1 (en) | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
CA2788826C (en) * | 2010-02-05 | 2023-09-26 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
WO2013151688A1 (en) * | 2012-04-06 | 2013-10-10 | Georgia Regents University | Methods and compositions for using insulin-like growth factor binding protein 6 in treating and diagnosing diabetes |
CN110577589B (en) * | 2018-06-11 | 2023-04-14 | 朱伟东 | Insulin-like growth factor binding protein 4 mutant and pharmaceutical application thereof |
MA52870A (en) * | 2018-06-13 | 2021-04-21 | Acraf | PEPTIDES HAVING INHIBITORAL ACTIVITY ON THE MUSCARINIC M3 RECEPTOR |
WO2021097538A1 (en) * | 2019-11-22 | 2021-05-27 | The University Of Sydney | Bone formation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58110600A (en) | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | Recombinant plasmid containing human beta-interferon gene |
JPS60221091A (en) | 1983-12-21 | 1985-11-05 | Kyowa Hakko Kogyo Co Ltd | Novel promoter |
JP2564268B2 (en) | 1985-08-28 | 1996-12-18 | 協和醗酵工業株式会社 | Fusion antigen polypeptide |
JPH0322979A (en) | 1989-06-19 | 1991-01-31 | Kyowa Hakko Kogyo Co Ltd | Novel plasminogen-activation factor |
CA2148685A1 (en) * | 1992-11-04 | 1994-05-11 | Dennis L. Andress | Truncated insulin-like growth factor binding proteins having mitogenic activity |
US5597700A (en) * | 1994-04-28 | 1997-01-28 | California Research, Llc | Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method |
WO2000036105A1 (en) * | 1998-12-18 | 2000-06-22 | Human Genome Sciences, Inc. | Prostacyclin-stimulating factor-2 |
US20030148485A1 (en) * | 2000-03-20 | 2003-08-07 | Taupier Raymond J. | Novel polypeptides and nucleic acids encoding same |
EP1283255A4 (en) | 2000-04-27 | 2004-12-29 | Kyowa Hakko Kogyo Kk | Myocardial cell proliferation-associated genes |
AU6531101A (en) * | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
-
2001
- 2001-06-15 EP EP01941064A patent/EP1295939A4/en not_active Withdrawn
- 2001-06-15 WO PCT/JP2001/005112 patent/WO2001098493A1/en active Application Filing
- 2001-06-15 US US10/311,129 patent/US7071160B2/en not_active Expired - Fee Related
- 2001-06-15 AU AU2001274536A patent/AU2001274536A1/en not_active Abandoned
-
2006
- 2006-03-30 US US11/396,430 patent/US7332301B2/en not_active Expired - Fee Related
-
2008
- 2008-01-11 US US12/013,293 patent/US7858091B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7071160B2 (en) | 2006-07-04 |
WO2001098493A1 (en) | 2001-12-27 |
US20060216739A1 (en) | 2006-09-28 |
US7332301B2 (en) | 2008-02-19 |
US20040072238A1 (en) | 2004-04-15 |
EP1295939A4 (en) | 2005-02-02 |
US7858091B2 (en) | 2010-12-28 |
EP1295939A1 (en) | 2003-03-26 |
US20080241960A1 (en) | 2008-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002342653A1 (en) | Modified growth hormone | |
AUPR030900A0 (en) | Growth factor complex | |
AU6045900A (en) | Interaction-activated proteins | |
AU2001234893A1 (en) | Protein mapping | |
AU2001274536A1 (en) | Insulin-like growth factor-binding protein | |
AU2002950188A0 (en) | Altered insulin-like growth factor binding proteins | |
AU2190801A (en) | Binding protein | |
AU2001259450A1 (en) | Cytoskeleton-associated proteins | |
AU2001273208A1 (en) | Proteins associated with aging | |
AU2001244863A1 (en) | Apoptin-associating protein | |
AU2002239747A1 (en) | Cystoskeleton-associated proteins | |
AU2002243234A1 (en) | Embryogenesis associated proteins | |
AU2002211475A1 (en) | Site-specific protein modification | |
AU2001243693A1 (en) | Helical protein zalpha51 | |
AU2001262589A1 (en) | Glycosyltransferase proteins | |
AU2002246330A1 (en) | Insulin-like growth factor-binding protein | |
AU2964700A (en) | Bone marrow-specific protein | |
AU2001278975A1 (en) | Alpha-conotoxin peptides | |
AU2001278777A1 (en) | Irap-binding protein | |
AU2002240889A1 (en) | Proteins that interact with betatrcp | |
AU2001284748A1 (en) | Reaper protein | |
AU2001241044A1 (en) | Mitf-associated proteins | |
AU2001238415A1 (en) | Gtpase activating proteins | |
AU2001263445A1 (en) | Methods for protein design | |
AU6444600A (en) | New protein |